Developing small-molecule treatments to reverse the debilitating impact of degenerative diseases
Frequency is pioneering a new category in regenerative medicine, developing small-molecule therapeutics to selectively activate progenitor cells already present within the body to create healthy, functional tissues.
Sensorineural Hearing Loss (SNHL)
Stage: Phase 2
Study of noise induced and sudden SNHL patients, ages 18 – 65.
Study enrolling 124 subjects, first subject dosed October 2021
Our Program for Sensorineural Hearing Loss
Advancing FX-322 into a Phase 2b clinical study for the most common form of hearing lossLearn More
Our Program for Multiple Sclerosis
Developing medicines that activate the cells needed to restore myelin, potentially reversing damage done by multiple sclerosisLearn More